Pharma BD Deal Intelligence
Laboratory Corporation of America Holdings / OPKO Health, Inc.
2025 · Asset Purchase · $225M · Pending
OPKO Health and its wholly owned subsidiary BioReference Health, LLC agreed to sell to Laboratory Corporation of America Holdings certain assets and liabilities of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States, for an aggregate purchase price of up to $225 million in cash.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Mar 10, 2025
- Deal value $225M
- Deal type Asset Purchase
- Therapeutic area Oncology
- Key assets BioReference Health oncology and oncology-related clinical testing business (US)
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Oncology deals